Riddhi Siddhi Gluco Biols Q4 FY26 Results: Loss Rs 33 Cr

Riddhi Siddhi Gluco Biols Q4 FY26 results were declared on May 25, 2026. The company reported net loss of Rs 33 crore for the quarter ended March 31, 2026, down 760.0% YoY compared to Rs 5 crore in Q4 FY25. Revenue from operations was Rs 9 crore, down 67.9% YoY. Results are on a Consolidated basis. Riddhi Siddhi Gluco Biols is a Starch and Biochemicals company listed on Indian stock exchanges.

Click Here – Get Free Investment Predictions

Riddhi Siddhi Gluco Biols Q4 FY26 Financial Highlights

Metric	Q4 FY26 (Rs Cr)	Q4 FY25 (Rs Cr)	YoY Change
Revenue	Rs 9 crore	Rs 28 crore	-67.9%
Net Loss	33	5	-760.0%
Basis	Consolidated

Note: Riddhi Siddhi Gluco Biols Q4 FY26 results declared May 25, 2026. Data sourced from Screener.in BSE filings. Verify from audited statements before investment decisions.

Riddhi Siddhi Gluco Biols Q4 FY26 Performance Analysis

The Riddhi Siddhi Gluco Biols Q4 FY26 results reflect the company’s financial performance during the January to March 2026 quarter. The quarter shows near-term profitability challenges requiring management focus in FY27. Riddhi Siddhi Gluco Biols operates in the Starch and Biochemicals sector, which benefits from India’s GDP growth above 6.5% in FY26.

Revenue of Rs 9 crore was down 67.9% YoY. Revenue moderation reflects near-term demand headwinds.

Screen the best stocks on the Univest Screener.

Key Factors Driving Riddhi Siddhi Gluco Biols Q4 FY26 Results

Revenue and Business Execution

Revenue of Rs 9 crore in Riddhi Siddhi Gluco Biols Q4 FY26 was down 67.9% YoY. Revenue pressure reflects near-term demand headwinds in the Starch and Biochemicals market. The January to March quarter is the fiscal year-end period characterised by strong order execution and year-end activity across Indian companies.

Profitability and Margin Trends

The Riddhi Siddhi Gluco Biols Q4 FY26 net loss of Rs 33 crore down 760.0% YoY. Net loss reflects ongoing operational challenges with FY27 recovery as management’s focus.

India Macro Environment Q4 FY26

India’s macroeconomic environment in Q4 FY26 was supportive with GDP growth above 6.5%, government capex of Rs 11.21 lakh crore budgeted for FY27, and resilient domestic consumption. The Reserve Bank of India’s accommodative stance supported credit conditions. The Starch and Biochemicals sector benefited from these structural tailwinds during the January to March 2026 quarter.

FY27 Outlook

Following the firm results, management guidance on FY27 revenue growth, margin improvement roadmap, and capital allocation priorities will be key investor watchpoints. The Starch and Biochemicals sector continues to benefit from India’s long-term structural growth story including urbanisation, infrastructure investment, and rising domestic consumption. Returning to profitability through operational improvements will define the FY27 strategy.

Download the Univest iOS App or the Univest Android App to get daily stock recommendations and expert research.

Frequently Asked Questions on the company

Investments in securities are subject to market risk. This content is for educational purposes only. Verify all figures from BSE/NSE filings. Consult a SEBI-registered financial advisor.